Raf-1 phosphorylates and activates MEK-1, a kinase that activates the extracellular signal regulated kinases (ERK). This kinase cascade controls the proliferation and differentiation of different cell types 1, 2 . Here we describe a Raf-1-interacting protein, isolated using a yeast two-hybrid screen. This protein inhibits the phosphorylation and activation of MEK by Raf-1 and is designated RKIP (Raf kinase inhibitor protein). In vitro, RKIP binds to Raf-1, MEK and ERK, but not to Ras. RKIP co-immunoprecipitates with Raf-1 and MEK from cell lysates and colocalizes with Raf-1 when examined by confocal microscopy. RKIP is not a substrate for Raf-1 or MEK, but competitively disrupts the interaction between these kinases. RKIP overexpression interferes with the activation of MEK and ERK, induction of AP-1-dependent reporter genes and transformation elicited by an oncogenically activated Raf-1 kinase. Downregulation of endogenous RKIP by expression of antisense RNA or antibody microinjection induces the activation of MEK-, ERK-and AP-1-dependent transcription. RKIP represents a new class of protein-kinase-inhibitor protein that regulates the activity of the Raf/MEK/ERK module.
In metazoans the Ras/Raf-1/MEK/ERK module is a ubiquitously expressed signalling pathway that conveys mitogenic and differentiation signals from the cell membrane to the nucleus 1 . This kinase cascade appears to be spatially organized in a signalling complex that is nucleated by Ras proteins 3 . The regulation of the Ras/Raf-1/ MEK/ERK module is complex and may include associations with scaffolding and regulatory proteins 4 . To isolate such proteins we used the Raf-1 kinase domain, BXB 5 , as bait in a yeast two-hybrid screen 6 . Screening 500,000 clones of a human T-cell library yielded nine clones that speci®cally interacted with BXB. Five clones corresponded to 14-3-3 proteins. One clone, RKIP, bound to both kinase-active and kinase-negative BXB, but not to control baits (Fig. 1a) . Partial sequencing of the RKIP complementary DNA predicted a protein identical to the phosphatidylethanolamine binding proteins (PEBP) with relative molecular mass 23,000 (M r 23K) from humans and monkeys. These proteins are widely expressed and evolutionarily conserved, but their functions remain obscure 7 . Puri®ed recombinant RKIP was tested for binding to the components of the Ras/Raf-1/MEK/ERK cascade. RKIP associated with BXB, full-length Raf-1, MEK-1 and (more weakly) with ERK-2, but not with Ras. RKIP binding was independent of Raf-1 kinase activity, not affected by phosphatidylethanolamine, and direct, as shown by the interaction of puri®ed proteins produced in Escherichia coli (Fig. 1b and data not shown) .
These interactions were also shown between endogenous mammalian proteins. An RKIP antiserum co-immunoprecipitated Raf-1, MEK and ERK from Rat-1 cells. This was not due to crossreactivity, because the RKIP antiserum failed to immunoprecipitate puri®ed Raf-1, MEK-1 or ERK-2 individually (Fig. 1c) . These interactions were also observed in reciprocal immunoprecipitations with antisera to Raf-1, MEK or ERK (data not shown). Confocal microscopy revealed extensive colocalization between Raf-1 and RKIP, in both quiescent and Ras-transformed cells (Fig. 1d) .
To investigate the relevance of the interaction between RKIP and the kinases of the Raf/MEK/ERK module in mammalian cells, we inhibited endogenous RKIP by antibody microinjection or expression of antisense RNA. As the AP-1 transcription factor is a major target of Raf signalling
8±10
, we tested the in¯uence of RKIP on AP-1 activity (Fig. 2a) . Microinjection of af®nity-puri®ed anti-RKIP antibodies robustly activated a co-injected AP-1-dependent reporter gene in serum-deprived Rat-1 ®broblasts (Fig. 2a) . This effect was highly speci®c, because the injection of control immunoglobulin (IgG) was ineffective, anti-RKIP IgG did not affect the expression of a cAMP-dependent reporter gene, and co-injection of an RKIP expression vector abolished AP-1 induction by anti-RKIP IgG. We also downregulated RKIP expression using an RKIP antisense vector, pAS-C143. This vector markedly reduced RKIP levels without affecting the expression of MEK-1 or actin (Fig. 2b) . pAS-C143 substantially induced the AP-1 reporter gene in serum-starved NIH 3T3 cells (Fig. 2c) . These data con®rm the microinjection results and show that RKIP suppresses the Raf/MEK/ERK pathway.
Overexpression experiments further con®rmed this conclusion. RKIP transfection diminished basal as well as BXB-induced AP-1 activity (Fig. 3a) , and microinjection of an RKIP expression vector impaired AP-1 induction by BXB (Fig. 3b) . Notably, RKIP did not interfere with AP-1 stimulation by ERK-1. Next, we tested the effects of RKIP overexpression in transformation assays. In contrast to transient reporter-gene assays, transformation assays accommodate the complexity of cellular responses to the chronic deregulation of a single signalling component. RKIP signi®cantly reduced the transformation ef®ciency of BXB in three distinct assays: morphological transformation, focus formation and anchorage-independent growth (Fig. 3c) . RKIP also decreased the total colony yield, albeit to a lesser extent than transformation, showing that RKIP interferes with Raf-mediated proliferation as well as transformation. In contrast, RKIP impaired the induction of foci by v-fos or mutationally activated MEK alleles only to a small extent, and failed to inhibit v-src transformation (Fig. 3d ), indicating that RKIP may speci®cally block transformation by the Raf/MEK/ERK pathway, primarily by inhibiting Raf.
To investigate the effects of RKIP on individual activation steps, we reconstructed the Raf/MEK/ERK cascade in vitro using recombinant proteins (Fig. 4a) . RKIP decreased the phosphorylation of MEK by Raf-1, but did not inhibit ERK phosphorylation by MEK or ELK phosphorylation by ERK. In addition, RKIP (1) failed to inhibit MEK-DD, a constitutively active mutant of MEK 11 , or MEK activated by TPA treatment of cells (Fig. 4b) ; (2) prevent MEK phosphorylation by MEKK-1 (Fig. 4c) ; and (3) did not interfere with Raf-1 autophosphorylation or phosphorylation of myelin basic protein (MBP) by Raf-1 (Fig. 4d) . These data indicate that RKIP is a very selective inhibitor that speci®cally blocks activation of MEK by Raf.
In vitro, RKIP disrupted the physical interaction between Raf-1 and MEK, which is required for MEK phosphorylation 12 , and behaved like a competitive inhibitor for MEK (data not shown). Therefore, we investigated whether this mechanism also operated in cells. The downregulation of endogenous RKIP expression by the pAS-C143 antisense vector substantially enhanced phosphorylation of MEK on activation-speci®c sites (Fig. 5a) . Similarily, microinjection of RKIP antibodies enhanced ERK activation in NIH 3T3 cells (Fig. 5b) . In a complementary approach, RKIP was over-expressed. Cotransfection of RKIP had only a small in¯uence on the activation of Raf-1 by TPA, but strongly inhibited the activation of MEK in a dose-dependent fashion (Fig. 5c) . EGF produced the same results (data not shown). RKIP overexpression also downregulated the activation of ERKs by the v-Ras or v-Src oncogenes (Fig. 5d) . Cotransfection of increasing amounts of an RKIP expression plasmid inhibited the BXB-induced activation of ERK in a dosedependent manner. In contrast, RKIP did not affect activation by ERK by MEK-DD (Fig. 5e) . These data con®rm the in vitro results (Fig. 4) , and show that RKIP regulates the ERK pathway primarily at the Raf/MEK interface in vivo.
To test whether the association between Raf and RKIP changes during mitogenic stimulation, we monitored the presence of RKIP in Raf-1 immunoprecipitates prepared from Rat-1 cells at different times after stimulation with serum (Fig. 6) . The activation kinetics of the ERK pathway closely correlated with a decrease in RKIP coprecipitation. Furthermore, as the activity of the ERK pathway returned to basal levels at later times following mitogenic stimulation, the interaction between Raf-1 and RKIP returned to the level seen in quiescent cells.
What could be the physiological role of an inhibitor such as RKIP? Like the ERK pathway, RKIP is widely expressed. A quanti®cation of Raf-1, MEK, ERK and RKIP protein levels in the cell lines used in this study showed a wide variation in RKIP expression relative to the kinases. The ratio Raf-1:MEK:ERK:RKIP was 1:1.6:2.4:14 in Rat-1; 1:1.4:3.5:27 in 208F; 1:0.7:9:4.2 in NIH 3T3; and 1:2.9:5.9:,1.9 in COS-1 cells. Thus, at least in the three ®broblast cells lines, RKIP is abundant enough to be stoichiometrically relevant as an inhibitor. RKIP also colocalized with Raf-1 in Ras-transformed cells (Fig. 1d) , indicating that an appreciable fraction of Raf-1 and its inhibitor RKIP may remain associated even under conditions that promote Raf-1 activation. This may in part explain the observation that only a small fraction of Raf-1 can be activated 13 . We propose that RKIP could function like a rheostat that sets the sensitivity threshold for the activation of the Raf/MEK/ ERK pathway. A quantitative analysis of the activation kinetics of the ERK pathway showed that this cascade operates like a switch that suppresses background noise but strongly ampli®es signals exceeding a certain threshold 14 . Overexpression of RKIP raises this threshold, whereas downregulation of RKIP lowers it. As the amplitude, kinetics and overall duration of ERK activity are known to vary between biological responses such as cell-cycle arrest, transformation, mitogenesis and differentiation 1,15±18 , RKIP is expected to exert a profound in¯uence on these parameters. M
Methods

Plasmids and protein expression
The rat RKIP cDNA 19 was cloned (1) into pcDNA3 to make p353/RKIP; (2) into pCMV5 with a triple HA-tag at the amino-terminus; and (3) into pGEX-KG to make GST±RKIP. pAS-C143 encompasses RKIP nucleotides 1±429 cloned into pCMVori in antisense orientation. pCMVori contains the CMV promoter, polylinker and polyadenylation sequences from pCMV5 inserted into pUCori upstream of the polyoma virus core origin 20 . 6xHis-tagged MEK-and GST-fusion proteins were expressed and puri®ed as described 21 . RKIP of .95% purity was prepared from GST±RKIP by thrombin cleavage 22 and subsequent FPLC separation over Superose 12.
In vitro binding assays
These contained 1±5 mg of GST-fusion protein immobilized on glutathione sepharose beads and 0.5±5 mg puri®ed recombinant protein in PBS supplemented with 10% bovine serum as a nonspeci®c competitor. Sf-9 cell lysates were used as a source of Raf proteins 21 . After incubation for 1 h at 4 8C the samples were washed 4 times with PBS, resolved by SDS±PAGE and blotted. The blots were developed using ECL (Amersham). 
Immunoprecipitation
For co-precipitation experiments of endogenous proteins, 2 3 10 7 Rat-1 cells were lysed by sonication in PBS, and the immunoprecipitates were washed 4 times with PBS. Otherwise cells were lysed as described 21 . The antibodies used were crafVI, a peptide antibody against the 12 carboxy-terminal amino acids of Raf-1 (ref. 21); a Raf monoclonal antibody to the regulatory domain (Transduction Laboratories); anti-MEK H8 (Santa Cruz); anti-RKIP raised in rabbits immunized with puri®ed GST±RKIP; anti-HA, 12CA5 monoclonal antibody; monoclonal anti-phospho-ERK (Sigma) and polyclonal antiphospho-MEK antibodies (New England Biolabs); and anti-GST (Pharmacia).
Kinase assays
These were done as described 21 . For in vitro reconstruction of the Raf/MEK/ERK cascade, activated Raf-1 was generated by co-expressing GST±Raf-1 with v-Ras and Lck in Sf-9 cells and collected on glutathione-sepharose beads 21 . Subsequent thrombin cleavage released Raf-1, which was fully active and .90% pure. To activate MEK and ERK in vitro, 20 ng of activated Raf-1 was incubated with 40 ng of puri®ed His/MEK-1 and 250 ng of GST±ERK-2 in Raf kinase buffer containing 20 mM ATP for 20 min at 30 8C. To measure kinase activities at individual steps, the respective downstream components were omitted. The activation reactions were diluted into 50 ml Raf kinase buffer 21 containing 20 mM ATP to yield equimolar concentrations of the kinases to be assayed and incubated with increasing amounts of puri®ed RKIP on ice for 10 min. Then, 2 mCi[ 32 P]-g-ATP and recombinant substrates were added and incubated for 20 min at 30 8C. As substrates, we used 200 ng kinase negative His/MEK-1 for Raf, 1 mg kinase negative GST±ERK for MEK and 1 mg GST±ELK (New England Biolabs) for ERK. In some assays 1 mg GST±MEKwas used as the Raf-1 substrate with identical results.
Transfections
COS-1 cells were transfected as described 23 with 2 mg of HA±ERK-2, BXB, MEK and MEK-DD plasmids and the indicated amounts of p353/RKIP. The total amount of transfected DNA was kept constant using the appropriate vectors as carrier DNA. NIH 3T3 and 208F cells were transfected in 6-well plates with 1 mg of pCMV5-BXB and 3 mg of p353/RKIP using Superfect (Qiagen). For RKIP downregulation experiments, NIH 3T3 cells were transiently cotransfected using lipofectamine with 0.5 mg of pHACT 20 and 1.5 or 3 mg RKIP antisense expression vector (pAS-C143) or control vector (pCMVori) as indicated. pHACTexpresses a truncated polyoma large-T construct with origin-binding activity, but does not bind Rb or p53, and boosts the expression of pAS-C143 to high levels. In addition, 0.1 mg of an AP1-Luc reporter was transfected for reporter-gene assays. 48 hours after transfection, cells were serum starved for 20 h and either left untreated or treated with TPA (200 ng ml -1 ) or serum for 5 h before being collected. Cells were lysed and cell extracts were used for immunoblotting or assayed for luciferase activity. For the green¯uorescent protein (GFP) sorting experiments, 5 3 10 6 NIH 3T3 cells were electroporated with either 100 mg pCMVori, 50 mg pCMV±GFP and 50 mg pHACT, or 100 mg pASC143, 50 mg CMV±GFP and 50 mg CMV±HAC. Two days later cells were trypsinized and sorted for green¯uorescent cells by preparative FACS. 100,000 GFP-positive cells were lysed in SDSgel sample buffer and immunoblotted.
Microinjection
Microinjection of antibodies and reporter genes was done as described 24, 25 . The RKIP antiserum was puri®ed over a GST±RKIP af®nity column. Cells were stained with an activation-speci®c anti-phospho-ERK monoclonal antibody (New England Biolabs). ERK phosphorylation was quanti®ed by densitometry. For this purpose areas with microinjected cells were randomly photographed, and the staining intensity of whole individual cells was measured using the PcBAS software.
